Developer docs
API playgroundTry for free, no card

Search company profiles

Fuho Capital

Full company profile

uuid0027ybu

Namestring
Fuho Capital
Legal namestring
富汇创新创业投资管理有限公司
Websiteurl
fuhocapital.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Fuho Capital (富汇创新创业投资管理有限公司) is a private, Beijing-based venture capital and investment management firm founded in 2008. It serves early-stage companies commercializing technologies from research institutions, with a stated focus on healthcare and pharmaceuticals, TMT, and advanced manufacturing. The firm reports 18 funds, more than RMB 4 billion in assets under management, more than 100 portfolio projects, and at least 15 portfolio companies that have achieved an IPO or public listing.

Fuho does not develop a proprietary core technology. Its investment portfolio covers businesses developing regenerative medicine, AI-enabled drug discovery, hydrogen and liquid-hydrogen systems, laser display, cellular therapy, medical devices, semiconductors, and other advanced-manufacturing technologies. Its investment cases are organized into healthcare, technology-transfer, TMT and advanced-manufacturing, and listed or quoted-company categories. These are investee technologies and portfolio categories, not internally developed products or platforms.

Fuho makes direct equity investments and describes its return mechanics as ownership stakes, capital appreciation, dividends, and proceeds from IPOs, M&A transactions, or secondary sales. It raises capital from institutional investors and deploys it into Chinese technology companies, with deal sourcing conducted through direct outreach, industry conferences, and partnerships involving research institutions such as the Chinese Academy of Sciences. The materials do not disclose management-fee rates, carried-interest participation, fund terms, realized investment income, or product pricing.

Short descriptiontext

Fuho Capital is a Beijing-based private venture capital and investment management firm serving early-stage technology companies in healthcare, advanced manufacturing, and TMT through fund investments and commercialization support from research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHaidian, China
HQ citystring
Haidian
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital management, early-stage technology investment, technology transfer financing, biotech equity investment, advanced manufacturing venture
Industry1 code
PRIMARYFSANAGAC
Venture Capital Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code2 codes
  • Other Investment Pools and Funds5259
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Fuho Capital generates returns through equity investments in early-stage technology companies. The firm takes ownership stakes in portfolio companies and realizes returns through exit events such as IPOs, M&A transactions, or secondary sales. Revenue is derived from capital appreciation and any dividend distributions from portfolio companies.

fuhocapital.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Fuho Capital is a private venture capital and investment management firm that manages 18 funds with over 4 billion RMB in assets under management, providing equity capital and strategic support to early-stage technology companies commercializing scientific research from institutions such as the Chinese Academy of Sciences. Its investment portfolio spans healthcare/biotech, TMT, advanced manufacturing, and technology transfer sectors, with 100+ portfolio companies and 15+ IPOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 18+ years operating in early-stage tech transfer
+3 more records
Product overview1 text field

Fuho Capital (富汇创新创业投资管理有限公司) is a venture capital and investment management firm specializing in early-stage technology transfer and commercialization since 2008. The firm manages 18 funds with over 4 billion RMB in assets under management and has invested in over 100 portfolio companies. Its core offering is investment management services in the healthcare/pharma, TMT/advanced manufacturing, and technology transfer sectors, targeting early-stage companies commercializing scientific research from institutions like the Chinese Academy of Sciences. The investment portfolio includes four main categories: Healthcare (医药健康) covering biotech and medical devices, TMT/Advanced Manufacturing (TMT/先进制造) covering display technology and hydrogen energy, Technology Transfer (科技成果转化) for research commercialization, and Listed Companies (已上市/挂牌) for post-IPO holdings.

Product and service2 records
1Investment Management Services
CategoryCore service
Description

Venture capital and investment management services focused on early-stage technology transfer and commercialization, managing 18 funds with over 4 billion RMB in AUM.

2Healthcare/Pharma Investment (医药健康)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1中国科学院上海药物研究所 (Shanghai Institute of Materia Medica, CAS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term strategic partnership for drug innovation system co-construction; Fuho Capital serves as long-term strategic partner of SIMM, jointly promoting biomedical industry development in Zhongshan through technology transfer collaboration

fuhocapital.com
2中山药物创新研究院 (Zhongshan Institute for Drug Innovation)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cooperation platform for innovative drug R&D in Greater Bay Area; jointly hosts industry summits and signs strategic cooperation agreements

fuhocapital.com
3中国电子科技集团 (China Electronics Technology Group)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology transfer partner; Jixiang Technology is a CETC-approved technology transfer and mixed-ownership reform enterprise

fuhocapital.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

China-focused VC concentrated in enterprise software, deep tech, and biotech. Comparable to Fuho's TMT and advanced manufacturing portfolio, though Source Code skews more toward software/digital plays than tech-transfer origin companies.

TypeDirect peer
Description

Early-stage technology VC affiliated with Legend Holdings, focused on AI, biotech, and advanced manufacturing startups. Highly comparable to Fuho's early-stage tech-transfer mandate and similar portfolio stage and check sizes.

3BioVeda Capital (弘晖资本)
TypeDirect peer
Description

China-focused healthcare VC investing in biotech, medical devices, and CRO/services. Closely comparable to Fuho's healthcare/biotech vertical and similar check sizes for clinical and pre-commercial stage companies.

TypeDirect peer
Description

Early-stage technology VC active across healthcare, advanced manufacturing, and digital sectors in China. Directly comparable to Fuho in stage and sector focus, with stronger brand recognition and larger average fund sizes.

5CDH Investments (鼎晖投资)
TypeBroad incumbent
Description

Major Chinese private equity and venture capital platform with healthcare, TMT, and industrial growth funds. Comparable to Fuho on healthcare/biotech exposure but spans later stages and substantially larger deal sizes.

6Shenzhen Capital Group (深创投)
TypeBroad incumbent
Description

One of China's largest state-backed venture capital firms with broad sector coverage across technology, healthcare, and advanced manufacturing. A broader incumbent competitor with substantially larger fund sizes and broader LP backing than Fuho.

TypeDirect peer
Description

Early-to-growth-stage VC focused on technology, healthcare, and clean energy. Directly comparable to Fuho across its three core sectors (healthcare/biotech, TMT/advanced manufacturing, energy) with a longer operating history.

TypeBroad incumbent
Description

Global VC with deep China franchise investing across technology, healthcare, and consumer. Comparable to Fuho on tech-transfer-adjacent bets, but operates at much larger scale with diversified stage exposure.

TypeDirect peer
Description

Leading China-focused VC with deep healthcare/biotech and TMT franchises. Comparable to Fuho given overlapping healthcare portfolio emphasis (e.g., New Horizon Health-style bets) and similar stage focus, though Qiming operates at materially larger fund scale.

TypeDirect peer
Description

CAS-affiliated venture capital firm co-founded by Fuho's chairman Zeng Jun in 2017. Specializes in commercializing Chinese Academy of Sciences research outcomes across biotech, advanced manufacturing, and TMT, making it the most directly comparable peer in mission, sector focus, and deal sourcing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment34 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fuho Capital

Venture Capital Managementfuhocapital.com

Fuho Capital is a Beijing-based private venture capital and investment management firm serving early-stage technology companies in healthcare, advanced manufacturing, and TMT through fund investments and commercialization support from research institutions.

What Fuho Capital does

Fuho Capital (富汇创新创业投资管理有限公司) is a private, Beijing-based venture capital and investment management firm founded in 2008. It serves early-stage companies commercializing technologies from research institutions, with a stated focus on healthcare and pharmaceuticals, TMT, and advanced manufacturing. The firm reports 18 funds, more than RMB 4 billion in assets under management, more than 100 portfolio projects, and at least 15 portfolio companies that have achieved an IPO or public listing.

Fuho does not develop a proprietary core technology. Its investment portfolio covers businesses developing regenerative medicine, AI-enabled drug discovery, hydrogen and liquid-hydrogen systems, laser display, cellular therapy, medical devices, semiconductors, and other advanced-manufacturing technologies. Its investment cases are organized into healthcare, technology-transfer, TMT and advanced-manufacturing, and listed or quoted-company categories. These are investee technologies and portfolio categories, not internally developed products or platforms.

Fuho makes direct equity investments and describes its return mechanics as ownership stakes, capital appreciation, dividends, and proceeds from IPOs, M&A transactions, or secondary sales. It raises capital from institutional investors and deploys it into Chinese technology companies, with deal sourcing conducted through direct outreach, industry conferences, and partnerships involving research institutions such as the Chinese Academy of Sciences. The materials do not disclose management-fee rates, carried-interest participation, fund terms, realized investment income, or product pricing.

Fuho Capital firmographics

Firmographics
Name
Fuho Capital
Legal name
富汇创新创业投资管理有限公司
Website
https://fuhocapital.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Fuho Capital is a Beijing-based private venture capital and investment management firm serving early-stage technology companies in healthcare, advanced manufacturing, and TMT through fund investments and commercialization support from research institutions.
Ownership category
akta.pro rank

Fuho Capital industry classification

Industry
Product category
Venture Capital Management
NAICS
Other Investment Pools and Funds (5259), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAC
Venture Capital Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital management
  • Early-stage technology investment
  • Technology transfer financing
  • Biotech equity investment
  • Advanced manufacturing venture

Where Fuho Capital is headquartered

Location

Headquarters

HQ city
Haidian
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Fuho Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Returns: Fuho Capital generates returns through equity investments in early-stage technology companies. The firm takes ownership stakes in portfolio companies and realizes returns through exit events such as IPOs, M&A transactions, or secondary sales. Revenue is derived from capital appreciation and any dividend distributions from portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Fuho Capital product offering

Product offering

Core offering

Fuho Capital is a private venture capital and investment management firm that manages 18 funds with over 4 billion RMB in assets under management, providing equity capital and strategic support to early-stage technology companies commercializing scientific research from institutions such as the Chinese Academy of Sciences. Its investment portfolio spans healthcare/biotech, TMT, advanced manufacturing, and technology transfer sectors, with 100+ portfolio companies and 15+ IPOs.

Product overview

Fuho Capital (富汇创新创业投资管理有限公司) is a venture capital and investment management firm specializing in early-stage technology transfer and commercialization since 2008. The firm manages 18 funds with over 4 billion RMB in assets under management and has invested in over 100 portfolio companies. Its core offering is investment management services in the healthcare/pharma, TMT/advanced manufacturing, and technology transfer sectors, targeting early-stage companies commercializing scientific research from institutions like the Chinese Academy of Sciences. The investment portfolio includes four main categories: Healthcare (医药健康) covering biotech and medical devices, TMT/Advanced Manufacturing (TMT/先进制造) covering display technology and hydrogen energy, Technology Transfer (科技成果转化) for research commercialization, and Listed Companies (已上市/挂牌) for post-IPO holdings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Investment Management Services Venture capital and investment management services focused on early-stage technology transfer and commercialization, managing 18 funds with over 4 billion RMB in AUM.
  • Healthcare/Pharma Investment (医药健康)

Quantifiable outcome

  • 18+ years operating in early-stage tech transfer
  • +3 more outcomes

Companies that use Fuho Capital

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Fuho Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Fuho Capital partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • 中国科学院上海药物研究所 (Shanghai Institute of Materia Medica, CAS)coreStrategic or Co-development PartnerLong-term strategic partnership for drug innovation system co-construction; Fuho Capital serves as long-term strategic partner of SIMM, jointly promoting biomedical industry development in Zhongshan through technology transfer collaboration
  • 中山药物创新研究院 (Zhongshan Institute for Drug Innovation)coreStrategic or Co-development PartnerCooperation platform for innovative drug R&D in Greater Bay Area; jointly hosts industry summits and signs strategic cooperation agreements
  • 中国电子科技集团 (China Electronics Technology Group)coreStrategic or Co-development PartnerTechnology transfer partner; Jixiang Technology is a CETC-approved technology transfer and mixed-ownership reform enterprise

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Fuho Capital competitors and assessment

Company assessment

Emerging players

  • Source Code Capital (源码资本): China-focused VC concentrated in enterprise software, deep tech, and biotech. Comparable to Fuho's TMT and advanced manufacturing portfolio, though Source Code skews more toward software/digital plays than tech-transfer origin companies.

Direct peers

  • Legend Star (联想之星): Early-stage technology VC affiliated with Legend Holdings, focused on AI, biotech, and advanced manufacturing startups. Highly comparable to Fuho's early-stage tech-transfer mandate and similar portfolio stage and check sizes.
  • BioVeda Capital (弘晖资本): China-focused healthcare VC investing in biotech, medical devices, and CRO/services. Closely comparable to Fuho's healthcare/biotech vertical and similar check sizes for clinical and pre-commercial stage companies.
  • Matrixpartners China (经纬中国): Early-stage technology VC active across healthcare, advanced manufacturing, and digital sectors in China. Directly comparable to Fuho in stage and sector focus, with stronger brand recognition and larger average fund sizes.
  • Northern Light Venture Capital (北极光创投): Early-to-growth-stage VC focused on technology, healthcare, and clean energy. Directly comparable to Fuho across its three core sectors (healthcare/biotech, TMT/advanced manufacturing, energy) with a longer operating history.
  • Qiming Venture Partners (启明创投): Leading China-focused VC with deep healthcare/biotech and TMT franchises. Comparable to Fuho given overlapping healthcare portfolio emphasis (e.g., New Horizon Health-style bets) and similar stage focus, though Qiming operates at materially larger fund scale.
  • CAS Innovation Investment (中科院创投): CAS-affiliated venture capital firm co-founded by Fuho's chairman Zeng Jun in 2017. Specializes in commercializing Chinese Academy of Sciences research outcomes across biotech, advanced manufacturing, and TMT, making it the most directly comparable peer in mission, sector focus, and deal sourcing.

Broad incumbents

  • CDH Investments (鼎晖投资): Major Chinese private equity and venture capital platform with healthcare, TMT, and industrial growth funds. Comparable to Fuho on healthcare/biotech exposure but spans later stages and substantially larger deal sizes.
  • Shenzhen Capital Group (深创投): One of China's largest state-backed venture capital firms with broad sector coverage across technology, healthcare, and advanced manufacturing. A broader incumbent competitor with substantially larger fund sizes and broader LP backing than Fuho.
  • IDG Capital: Global VC with deep China franchise investing across technology, healthcare, and consumer. Comparable to Fuho on tech-transfer-adjacent bets, but operates at much larger scale with diversified stage exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Fuho Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fuho Capital leadership team

Management profile

Number of profiles

Profiles4 records

Fuho Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fuho Capital M&A and investment

M&A and investment

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fuho Capital

What does Fuho Capital do?

Fuho Capital is a private venture capital and investment management firm that manages 18 funds with over 4 billion RMB in assets under management, providing equity capital and strategic support to early-stage technology companies commercializing scientific research from institutions such as the Chinese Academy of Sciences. Its investment portfolio spans healthcare/biotech, TMT, advanced manufacturing, and technology transfer sectors, with 100+ portfolio companies and 15+ IPOs.

Is Fuho Capital a public or private company?

Fuho Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fuho Capital founded?

Fuho Capital was founded in 2008. It employs 11 to 50 people.

Where is Fuho Capital based?

Fuho Capital is headquartered in Haidian, China, in the Asia region.

How does Fuho Capital make money?

One revenue line is on record: investment Returns.

Who are Fuho Capital's main competitors?

Source Code Capital (源码资本) is listed as an emerging player. Direct peers are Legend Star (联想之星), BioVeda Capital (弘晖资本), Matrixpartners China (经纬中国), Northern Light Venture Capital (北极光创投), Qiming Venture Partners (启明创投) and CAS Innovation Investment (中科院创投). Broad incumbents are CDH Investments (鼎晖投资), Shenzhen Capital Group (深创投) and IDG Capital.

Does Fuho Capital have an API?

No public API is recorded for Fuho Capital.

What industry is Fuho Capital in?

Fuho Capital's product category is Venture Capital Management. Its primary akta.pro industry code is FSANAGAC, Venture Capital Fund-of-Funds. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales